Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis.

Chilosi M, Facchetti F, Caliò A, Zamò A, Brunelli M, Martignoni G, Rossi A, Montagna L, Piccoli P, Dubini A, Tironi A, Tomassetti S, Poletti V, Doglioni C.

Leuk Lymphoma. 2014 Nov;55(11):2620-6. doi: 10.3109/10428194.2014.887713. Epub 2014 Mar 10.

PMID:
24471909
2.

BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases.

Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, Vassallo R, Ryu JH, Yi ES.

Am J Surg Pathol. 2014 Apr;38(4):548-51. doi: 10.1097/PAS.0000000000000129.

PMID:
24625419
3.

Activating BRAF V600E mutation in aggressive pediatric Langerhans cell histiocytosis: demonstration by allele-specific PCR/direct sequencing and immunohistochemistry.

Méhes G, Irsai G, Bedekovics J, Beke L, Fazakas F, Rózsa T, Kiss C.

Am J Surg Pathol. 2014 Dec;38(12):1644-8. doi: 10.1097/PAS.0000000000000304.

PMID:
25118810
4.

Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis.

Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN.

Genes Chromosomes Cancer. 2013 Jan;52(1):99-106. doi: 10.1002/gcc.22010. Epub 2012 Sep 21.

PMID:
22996177
5.

Mutually exclusive extracellular signal-regulated kinase pathway mutations are present in different stages of multi-focal pulmonary Langerhans cell histiocytosis supporting clonal nature of the disease.

Kamionek M, Ahmadi Moghaddam P, Sakhdari A, Kovach AE, Welch M, Meng X, Dresser K, Tomaszewicz K, Cosar EF, Mark EJ, Fraire AE, Hutchinson L.

Histopathology. 2016 Sep;69(3):499-509. doi: 10.1111/his.12955. Epub 2016 Apr 29.

PMID:
26915300
6.

BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.

Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CC.

Hum Pathol. 2016 Jun;52:61-7. doi: 10.1016/j.humpath.2015.12.029. Epub 2016 Feb 1.

PMID:
26980021
7.

Recurrent BRAF mutations in Langerhans cell histiocytosis.

Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ.

Blood. 2010 Sep 16;116(11):1919-23. doi: 10.1182/blood-2010-04-279083. Epub 2010 Jun 2.

8.

Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation.

Hervier B, Haroche J, Arnaud L, Charlotte F, Donadieu J, Néel A, Lifermann F, Villabona C, Graffin B, Hermine O, Rigolet A, Roubille C, Hachulla E, Carmoi T, Bézier M, Meignin V, Conrad M, Marie L, Kostrzewa E, Michot JM, Barete S, Taly V, Cury K, Emile JF, Amoura Z; French Histiocytoses Study Group.

Blood. 2014 Aug 14;124(7):1119-26. doi: 10.1182/blood-2013-12-543793. Epub 2014 Jun 3.

9.

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay.

Tatsuno M, Shioda Y, Iwafuchi H, Yamazaki S, Iijima K, Takahashi C, Ono H, Uchida K, Okamura O, Matubayashi M, Okuyama T, Matsumoto K, Yoshioka T, Nakazawa A.

Diagn Pathol. 2016 Apr 19;11:39. doi: 10.1186/s13000-016-0489-z.

10.

Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.

Dimmler A, Geddert H, Werner M, Faller G.

Virchows Arch. 2017 Apr;470(4):429-435. doi: 10.1007/s00428-017-2092-4. Epub 2017 Feb 20.

PMID:
28220299
11.

Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer.

Kriegl L, Neumann J, Vieth M, Greten FR, Reu S, Jung A, Kirchner T.

Mod Pathol. 2011 Jul;24(7):1015-22. doi: 10.1038/modpathol.2011.43. Epub 2011 Mar 18.

12.

B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.

Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J, Geissmann F.

PLoS One. 2012;7(4):e33891. doi: 10.1371/journal.pone.0033891. Epub 2012 Apr 10. Erratum in: PLoS One. 2012;7(6). doi:10.1371/annotation/74a67f4e-a536-4b3f-a350-9a4c1e6bebbd. Mian, Sophie [corrected to Mian, Syed].

13.

Analysis of the BRAFV600E mutation in 19 cases of Langerhans cell histiocytosis in Japan.

Sasaki Y, Guo Y, Arakawa F, Miyoshi H, Yoshida N, Koga Y, Nakashima K, Kurita D, Niino D, Seto M, Ohshima K.

Hematol Oncol. 2017 Sep;35(3):329-334. doi: 10.1002/hon.2293. Epub 2016 Apr 4.

PMID:
27041734
14.

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS.

Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.

15.

Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation.

Johnson WT, Patel P, Hernandez A, Grandinetti LM, Huen AC, Marks S, Ho J, Monaco SE, Jaffe R, Picarsic J.

J Cutan Pathol. 2016 Mar;43(3):270-5. doi: 10.1111/cup.12636. Epub 2015 Nov 20.

PMID:
26454140
16.

Localized Langerhans cell histiocytosis of the thymus with BRAF V600E mutation: a case report with immunohistochemical and genetic analyses.

Oishi N, Kondo T, Mochizuki K, Inoue T, Kasai K, Nakazawa T, Mitsumori T, Katoh R.

Hum Pathol. 2014 Jun;45(6):1302-5. doi: 10.1016/j.humpath.2013.12.018. Epub 2014 Jan 21.

PMID:
24703101
17.

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrão M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE.

J Exp Med. 2014 Apr 7;211(4):669-83. doi: 10.1084/jem.20130977. Epub 2014 Mar 17. Erratum in: J Exp Med. 2015 Feb 9;212(2):281.

18.

Interleukin-1 loop model for pathogenesis of Langerhans cell histiocytosis.

Murakami I, Matsushita M, Iwasaki T, Kuwamoto S, Kato M, Nagata K, Horie Y, Hayashi K, Imamura T, Morimoto A, Imashuku S, Gogusev J, Jaubert F, Takata K, Oka T, Yoshino T.

Cell Commun Signal. 2015 Feb 22;13:13. doi: 10.1186/s12964-015-0092-z. Review.

19.

Langerhans cell histiocytosis in Chinese adults: absence of BRAF mutations and increased FOXP3(+) regulatory T cells.

Tong C, Jia X, Jia Y, He Y.

Int J Clin Exp Pathol. 2014 May 15;7(6):3166-73. eCollection 2014.

20.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J.

J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.

Supplemental Content

Support Center